Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ELV
ELV logo

ELV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
290.580
Open
287.220
VWAP
284.72
Vol
2.91M
Mkt Cap
62.39B
Low
280.915
Amount
829.77M
EV/EBITDA(TTM)
8.71
Total Shares
220.70M
EV
84.66B
EV/OCF(TTM)
19.73
P/S(TTM)
0.32
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
Show More

Events Timeline

(ET)
2026-03-10
06:40:00
Elevance Health Reaffirms 2026 EPS Guidance of At Least $25.50
select
2026-03-09 (ET)
2026-03-09
16:20:00
Myomo Enters Network Agreement with Elevance Health
select
2026-02-26 (ET)
2026-02-26
15:20:00
Company Reaffirms FY26 Benefit Expense Ratio Guidance at 90.2%
select
2026-02-26
15:10:00
Elevance Health Management Changes Simplify Decision-Making
select
2026-02-10 (ET)
2026-02-10
05:50:00
House Judiciary Committee Subpoenas Eight Health Insurers
select
link

News

Globenewswire
7.0
03-10Globenewswire
Elevance Health Under Investigation for Securities Fraud
  • Investigation Launched: Pomerantz LLP is investigating claims on behalf of Elevance Health investors regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns about corporate governance.
  • Regulatory Sanction Notice: On March 2, 2026, Elevance disclosed that CMS intends to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into its MA-PD plans, indicating significant compliance issues within the company.
  • Stock Price Decline: Following the sanction news, Elevance's stock price fell by $25.93, or 8.1%, closing at $294.07 per share on March 2, 2026, reflecting market concerns about the company's future outlook.
  • Compliance Risks: CMS indicated that the sanctions relate to Elevance's noncompliance with Medicare Advantage risk adjustment data submission requirements prior to April 3, 2023, which could have profound implications for the company's operations if not resolved by March 31, 2026.
Barron's
2.0
03-10Barron's
Centene Ranks as the Lowest Performing Stock in the S&P 500 Today: Here's the Reason.
  • Stock Performance: Centene's stock has underperformed compared to the broader market this year, reflecting challenges faced by health insurers and managed-care companies.
  • Regulatory Concerns: The company is navigating a changing regulatory environment, which has raised concerns among investors.
  • Business Update Impact: A recent business update from Centene has heightened investor anxiety regarding the company's future prospects.
  • Market Context: The struggles of Centene are indicative of broader issues within the health insurance sector amid evolving regulations.
NASDAQ.COM
5.0
03-06NASDAQ.COM
Insider Buying Activity in SLRC and ELV
  • SLRC Insider Purchase: Michael S. Gross acquired 104,819 shares of SLRC on Wednesday at $14.74 each, totaling an investment of $1.55 million, marking his first purchase in the past twelve months, indicating confidence in the company's future.
  • Market Price Comparison: On Friday, SLRC shares traded as low as $14.34, which is 2.7% below Gross's purchase price, reflecting short-term market volatility that may influence investor buying decisions.
  • ELV Insider Purchase: Elevance Health's Director Steven H. Collis bought 3,000 shares on Thursday at $289.84 each, totaling $869,520, signaling executive optimism regarding the company's prospects.
  • ELV Market Price Dynamics: On Friday, ELV shares traded as low as $281.50, which is 2.9% lower than Collis's purchase price, indicating market reactions that could affect other investors' confidence.
PRnewswire
7.0
03-06PRnewswire
Elevance Health Under Investigation for Securities Fraud
  • Investigation Launched: Pomerantz LLP is investigating on behalf of Elevance Health investors regarding potential securities fraud or other unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
  • CMS Sanction Notification: On March 2, 2026, Elevance disclosed that it was notified by CMS of intent to impose intermediate sanctions, suspending enrollment of Medicare beneficiaries into its Medicare Advantage-Prescription Drug plans and certain communication activities.
  • Compliance Issues: CMS indicated that the sanctions relate to Elevance's alleged noncompliance with Medicare Advantage risk adjustment data submission requirements prior to April 3, 2023, with sanctions set to take effect on March 31, 2026, unless satisfactorily addressed.
  • Stock Price Decline: Following this news, Elevance's stock price fell by $25.93, or 8.1%, closing at $294.07 per share on March 2, 2026, reflecting market concerns over the company's compliance capabilities.
CNBC
8.5
03-05CNBC
Eli Lilly Launches New Program to Enhance Obesity Drug Coverage
  • Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
  • Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
  • Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
  • Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.
Newsfilter
7.5
03-03Newsfilter
Elevance Health Partners with National Diaper Bank Network
  • Program Background: Elevance Health has partnered with the National Diaper Bank Network to launch a 12-month pilot program aimed at providing diapers to 9,000 families, alleviating financial strain while improving maternal and child health outcomes.
  • Coverage Scope: The initiative will distribute free diapers to up to 75 families per month at Welcome Rooms in 10 communities across the U.S., potentially reaching 9,000 families by 2026, directly addressing community needs.
  • Research Evaluation: The National Diaper Bank Network will conduct research to examine the relationship between diaper access and key maternal and child health indicators, focusing on caregiver stress, access to preventive care, and connections to family support services to inform future investments.
  • Strategic Significance: Elevance Health's Chief Growth Officer emphasized that this partnership not only alleviates financial burdens for families but also promotes maternal and child health by addressing basic needs, reflecting the company's commitment to community health.
Wall Street analysts forecast ELV stock price to rise
15 Analyst Rating
Wall Street analysts forecast ELV stock price to rise
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
332.00
Averages
389.07
High
425.00
Current: 0.000
sliders
Low
332.00
Averages
389.07
High
425.00
RBC Capital
Outperform -> Sector Perform
downgrade
$392 -> $358
AI Analysis
2026-02-03
Reason
RBC Capital
Price Target
$392 -> $358
AI Analysis
2026-02-03
downgrade
Outperform -> Sector Perform
Reason
RBC Capital downgraded Elevance Health to Sector Perform from Outperform with a price target of $358, down from $392. While "encouraged" by management's confidence in underlying performance, the firm is stepping to the sidelines on the softer than expected 2026 guidance and go-forward margin outlook, the analyst tells investors. The firm, which maintains its target PE multiple on its revised 2026 EPS, sees "little reason to reach beyond long-term historical average valuation levels," the analyst added.
JPMorgan
NULL -> Overweight
maintain
$394 -> $397
2026-02-02
Reason
JPMorgan
Price Target
$394 -> $397
2026-02-02
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Elevance Health to $397 from $394 and keeps an Overweight rating on the shares. The firm updated the company's model.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ELV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Elevance Health Inc (ELV.N) is 13.23, compared to its 5-year average forward P/E of 13.81. For a more detailed relative valuation and DCF analysis to assess Elevance Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
13.81
Current PE
13.23
Overvalued PE
15.62
Undervalued PE
12.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.30
Current EV/EBITDA
9.93
Overvalued EV/EBITDA
11.38
Undervalued EV/EBITDA
9.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.62
Current PS
0.39
Overvalued PS
0.74
Undervalued PS
0.50

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

who has earnings today’s
Intellectia · 83 candidates
List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MSFT logo
MSFT
Microsoft Corp
3.52T
META logo
META
Meta Platforms Inc
1.68T
TSLA logo
TSLA
Tesla Inc
1.44T
ASML logo
ASML
ASML Holding NV
567.84B
LRCX logo
LRCX
Lam Research Corp
281.28B
IBM logo
IBM
International Business Machines Corp
274.65B
which stocks should I buy?
Intellectia · 68 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Beta: LowRisk, ModerateRiskRevenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
Can you add a screener for me?A I
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
best beginner investment stocks
Intellectia · 91 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Beta: LowRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
WFC logo
WFC
Wells Fargo & Co
266.33B
RY logo
RY
Royal Bank of Canada
235.24B
SHEL logo
SHEL
Shell PLC
209.17B
¿Qué acción debería invertir sí o si
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
what is a good thing to in vest in now
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
What stock should I invest in
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
how to make a 1000000 in the stock market
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
where to invest 10000
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
best stocks to make money
Intellectia · 26 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 10Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
BBVA logo
BBVA
Banco Bilbao Vizcaya Argentaria SA
141.76B
COP logo
COP
ConocoPhillips
120.05B
ELV logo
ELV
Elevance Health Inc
82.20B

Whales Holding ELV

C
Crestline Investors Inc.
Holding
ELV
+13.24%
3M Return
D
Danske Bank A/S
Holding
ELV
+10.41%
3M Return
P
Polaris Capital Management, LLC
Holding
ELV
+9.28%
3M Return
F
Freestone Grove Partners LP
Holding
ELV
+5.73%
3M Return
F
First Eagle Investment Management, LLC
Holding
ELV
+5.65%
3M Return
Z
ZWJ Investment Counsel Inc
Holding
ELV
+5.09%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Elevance Health Inc (ELV) stock price today?

The current price of ELV is 282.68 USD — it has increased 0.69

What is Elevance Health Inc (ELV)'s business?

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.

What is the price predicton of ELV Stock?

Wall Street analysts forecast ELV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELV is389.07 USD with a low forecast of 332.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Elevance Health Inc (ELV)'s revenue for the last quarter?

Elevance Health Inc revenue for the last quarter amounts to 49.75B USD, increased 9.47

What is Elevance Health Inc (ELV)'s earnings per share (EPS) for the last quarter?

Elevance Health Inc. EPS for the last quarter amounts to 2.47 USD, increased 36.46

How many employees does Elevance Health Inc (ELV). have?

Elevance Health Inc (ELV) has 96129 emplpoyees as of March 11 2026.

What is Elevance Health Inc (ELV) market cap?

Today ELV has the market capitalization of 62.39B USD.